GLP-1 receptor agonists work. On that, the evidence is clear and the clinical enthusiasm is justified. Semaglutide produces average weight loss of around 15% in trial conditions. HbA1c improves. Cardiovascular risk markers shift. For patients with obesity and Type 2 diabetes who have struggled for years, these drugs represent a genuine clinical advance.
That is not what our article is about.
This is about what happens next. Because for the clinicians, insurers, and health system leaders who are making commissioning and prescribing decisions at scale, the drug's performance in a trial is only part of the story. The other part rarely makes it into the headline.
The number that changes the calculation
Between 50% and 75% of patients who start GLP-1 medication stop taking it within a year. Side effects, cost, access, and motivation all contribute. Researchers have described these as "staggeringly high" discontinuation rates — and the consequences are well documented.
The STEP 1 trial extension followed semaglutide patients after they stopped treatment. Within 12 months, participants had regained two-thirds of the weight they had lost. Cardiometabolic risk markers, which had improved during treatment, largely returned toward baseline. The biology rebounded because nothing had fundamentally changed in how these patients were living.
For an insurer covering Wegovy at £200 to £300 per month privately, or a clinic managing a chronic weight and diabetes caseload, this creates a specific problem. GLP-1 medication without behavioural support is not a treatment with an exit strategy. It is an indefinite cost line, effective only as long as the prescription continues.
What the drug does not do
Semaglutide suppresses appetite through neurological and hormonal pathways. It does not teach a patient how to manage hunger when the drug is no longer present. It does not build the decision-making habits around food and activity that survive a prescription lapse. It does not address the emotional and environmental factors that drove weight gain in the first place.
This distinction matters clinically, and it matters financially. The patients who maintain their results after stopping GLP-1 medication are overwhelmingly those who developed lifestyle skills alongside it; structured changes in eating patterns, sustainable movement habits, and the kind of self-regulation that comes from working through the behavioural drivers of their condition rather than around them.
A drug changes biology. A behaviour change programme changes what a person does when the drug is not there.
The combination that actually holds
The emerging consensus in obesity medicine is not GLP-1 versus lifestyle intervention. It is GLP-1 as an accelerant for lifestyle change; a window of reduced appetite and improved metabolic function during which the right behavioural support can build lasting skills. When the two are designed to work together, outcomes are qualitatively different from either approach alone.
For clinical programmes and insurer-funded services, this means the commissioning question is not just "which drug?" It is "what is the programme around the drug?" A prescription without structured support produces short-term results with high recidivism. A prescription within a behaviour change programme builds something the patient keeps.
How we approach this
Liva's chronic disease programmes are built for exactly this context. Our qualified coaches and dieticians work with patients on the COM-B framework, addressing capability, opportunity, and motivation simultaneously, to develop the behavioural foundations that sit alongside and outlast pharmacological intervention. Whether a patient is on GLP-1 medication or managing prediabetes and obesity through lifestyle alone, the coaching methodology is the same: build the skills that hold when nothing else is there.
If you are designing or commissioning a weight management or diabetes programme and want to understand how wraparound support changes long-term outcomes, talk to our team.
